It also demonstrated clinical efficacy in combination with abiraterone in patients with metastatic prostate cancer with or without PTEN loss, in combination with paclitaxel in locally advanced or metastatic triple-negative breast cancer in LOTUS trial, and in combination with abiraterone in mCRPC with PTEN loss in IPATential150 [208,209,210]. This evidence concerns the gene PTEN and metastatic prostate carcinoma.